Urodynamix Technologies Ltd.
TSX VENTURE : URO

Urodynamix Technologies Ltd.

February 21, 2007 08:50 ET

Urodynamix Discovers NIRS Application for Diagnosis of Erectile Dysfunction

Company completes feasibility study and initiates second ED clinical trial

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Feb. 21, 2007) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that it has initiated a second clinical study to evaluate the efficacy of its near-infrared spectroscopy ("NIRS") device for newly discovered applications related to the diagnosis and characterization of male erectile dysfunction ("ED"). This technology has been developed in collaboration with Dr. Sidney Radomski, MD, Associate Professor of Surgery (Urology) at the University of Toronto. Urodynamix has filed a patent application with the United States Patent and Trademark Office covering ED-related applications of NIRS technology.

Published data suggest that 20% of men affected by ED, or 3 to 5 million men in the United States alone, do not respond to medical treatment with oral PDE-5 inhibitors such as Viagra® (sildenafil citrate), Levitra® (vardenafil HCl) or Cialis® (tadalafil) and require alternative diagnosis and treatment. PDE-5 inhibitors have been used by over 38 million men worldwide, and are a first line therapy for most men with ED despite the fact that efficacy ranges from 71 to 76% (vs. 22 to 24% with placebo). Increasingly, PDE-5 therapy is being initiated by primary care physicians and the patient is referred to a urologist only when the medication appears to be ineffective.

Initial clinical studies carried out by Dr. Radomski have shown that NIRS can objectively and reproducibly measure blood flow throughout the penis. In addition to the sexual issues related to ED, the measurement of penile blood flow is of increasing interest because ED may be an early warning sign of heart disease. The February 20, 2007 edition of the Wall Street Journal reported that "men who aren't helped by (oral PDE-5 inhibitors) may be at higher risk for heart troubles and a vascular study of the penile arteries might be recommended".

The Company is initiating a new study on 12 male patients undergoing radical prostatectomy surgery to confirm that NIRS can measure differences in blood flow in patients before and after a bilateral nerve-sparing radical prostatectomy procedure. The study will be performed by Dr. Radomski and Drs. Sender Herschorn, MDCM, FRCSC, Professor and Chair of the University of Toronto's Division of Urology, and Jack Barkin, MD, FRCS(C), FACS, FICS, DABU, Chief of Urology at Humber River Regional Hospital and Director of The Male Health Centres in Toronto.

Radical prostatectomy is a standard treatment for prostate cancer that often causes intraoperative damage to the neurovascular mechanisms that initiate erections. Earlier detection of prostate cancer through the use of prostate-specific antigen screening has resulted in a significant increase in the number of prostatectomy procedures performed. The incidence of ED among these surgically treated patients is high, and has been attributed to vascular, veno-occlusive or nerve injury causes.

Urodynamix believes that there is a significant need for improved diagnosis in those men who do not respond to PDE-5 therapy, and that its proprietary NIRS technology will address an unmet medical need for improved ED diagnostics among men that suffer from this condition. This new NIRS application involves an extension of the Company's existing core NIRS technology and a new proprietary disposable sensor configuration. This market opportunity is estimated at 3 to 5 million men in the US alone.

About Erectile Dysfunction

Erectile dysfunction is the inability, over time, to consistently achieve or maintain an erection of sufficient rigidity for sexual intercourse. The causes of ED may be psychogenic in origin or related to penile trauma, spinal cord injuries, abnormalities of the penis, veno-occlusive dysfunction or radical pelvic surgery. ED may also be a secondary symptom of systemic diseases or their treatment, as in patients affected by diabetes mellitus, hypertension, blood lipid abnormalities, coronary artery disease or peripheral vascular disease.

Over 30 million American men suffer from ED, 85% of which is attributable to physical conditions. Published data suggest that in 1995 over 152 million men worldwide experienced ED, and by 2025 the prevalence of ED will have increased to approximately 322 million. This condition represents a serious challenge for healthcare policy makers seeking to prevent or alleviate ED and control healthcare expenditures.

In 2006, the American Urological Society's Erectile Dysfunction Clinical Guidelines Panel noted that "new, clinically applicable instruments are needed to diagnose ED and to assess treatment satisfaction". Other methods of vascular evaluation, such as cavernosometry or penile ultrasonography, remain controversial due to a lack of standardized diagnostic methods.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company's disruptive technology based on near-infrared spectroscopy (NIRS) has the potential to affect the diagnosis and treatment of 200 million people worldwide.

On behalf of the Board,

Barry Allen, President & CEO

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information